| A clinical focus on statins. | |
| | |
MedLine Citation:
|
PMID: 11575709 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Clinical trials have demonstrated that inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (statins) significantly reduce cardiovascular-related morbidity and mortality in patients with and without coronary artery disease. Furthermore, statins are currently the most potent cholesterol-lowering drugs available. Subanalyses of the LIPID study have shown that patients suffering from unstable angina pectoris had at least the same benefit from statin therapy as did patients after myocardial infarction. Studies, recently published (AVERT or MIRACL) provide more information on the topic of therapy with statins in the early phase of acute coronary syndromes. |
| | |
Authors:
|
J Auer; B Eber |
Related Documents
:
|
10559509 - Influence of serum triglyceride levels on the risk for myocardial infarction in 12,510 ... 15465509 - Effects of statins on stroke prevention in patients with and without coronary heart dis... 17697899 - Cholesterol reduction yields clinical benefits: meta-analysis including recent trials. 20027659 - Statin therapy decreases myocardial function as evaluated via strain imaging. 14980229 - The next step in cardiovascular protection. 1677109 - Aortic distensibility in patients with isolated hypercholesterolaemia, coronary artery ... 3409519 - Long-term follow-up of patients with left ventricular outflow tract obstruction after c... 10559509 - Influence of serum triglyceride levels on the risk for myocardial infarction in 12,510 ... 17470329 - Race-related differences in heart failure therapies: simply black and white or shades o... |
Publication Detail:
|
Type: Comparative Study; Journal Article; Review |
Journal Detail:
|
Title: Current opinion in investigational drugs (London, England : 2000) Volume: 2 ISSN: 1472-4472 ISO Abbreviation: Curr Opin Investig Drugs Publication Date: 2001 Mar |
Date Detail:
|
Created Date: 2001-09-28 Completed Date: 2001-12-04 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 100965718 Medline TA: Curr Opin Investig Drugs Country: England |
Other Details:
|
Languages: eng Pagination: 382-8 Citation Subset: IM |
Affiliation:
|
IInd Medicine Department with Cardiology and Intensive Care, General Hospital Wels, Austria. johann.auer@khwels.at |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Angina Pectoris
/
drug therapy,
therapy Angioplasty, Transluminal, Percutaneous Coronary Anticholesteremic Agents / economics, therapeutic use* Cholesterol / biosynthesis, blood Cholesterol, LDL / blood, metabolism Clinical Trials as Topic Coronary Disease / drug therapy*, metabolism, mortality Cost-Benefit Analysis Down-Regulation Fatty Acids, Monounsaturated / therapeutic use Heptanoic Acids / therapeutic use Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors / economics, therapeutic use* Indoles / therapeutic use Lovastatin / therapeutic use Multicenter Studies as Topic Myocardial Infarction / drug therapy*, metabolism Practice Guidelines as Topic Pravastatin / therapeutic use Pyrroles / therapeutic use Quality of Life Randomized Controlled Trials as Topic Simvastatin / therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Anticholesteremic Agents; 0/Cholesterol, LDL; 0/Fatty Acids, Monounsaturated; 0/Heptanoic Acids; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Indoles; 0/Pyrroles; 110862-48-1/atorvastatin; 57-88-5/Cholesterol; 75330-75-5/Lovastatin; 79902-63-9/Simvastatin; 81093-37-0/Pravastatin; 93957-54-1/fluvastatin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Reverse cholesterol transport and future pharmacological approaches to the treatment of atherosclero...
Next Document: S-8921 (Shionogi).